

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FI	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/940,101		08/27/2001	Mary E. Gerritsen	GENENT.072A2	4279
20995	7590	11/04/2003		EXAMINER	
		NS OLSON & BEA	BELYAVSKYI, MICHAIL A		
2040 MAIN FOURTEEN		OR		ART UNIT	PAPER NUMBER
IRVINE, C	RVINE, CA 92614			1644	
				DATE MAILED: 11/04/2003	3

Please find below and/or attached an Office communication concerning this application or proceeding.

•							
	Application No.	Applicant(s)					
Advisory Action	09/940,101	GERRITSEN ET AL.					
,, , ,	Examiner	Art Unit					
· · · · · · · · · · · · · · · · · · ·	Michail A Belyavskyi	1644	:				
The MAILING DATE of this communication appe	ears on the cover sheet with the	correspond nce add	ress				
THE REPLY FILED 16 October 2003 FAILS TO PLACE Therefore, further action by the applicant is required to av final rejection under 37 CFR 1.113 may only be either: (1) condition for allowance; (2) a timely filed Notice of Appeal Examination (RCE) in compliance with 37 CFR 1.114.	oid abandonment of this applica) a timely filed amendment whicl I (with appeal fee); or (3) a timel	ation. A proper reply h places the applica	/ to a tion in				
PERIOD FOR RE	EPLY [check either a) or b)]						
 a)	Advisory Action, or (2) the date set forth ater than SIX MONTHS from the mailin FILED WITHIN TWO MONTHS OF THe date on which the petition under 37 CF	g date of the final rejection HE FINAL REJECTION. R 1.136(a) and the appro	on. See MPEP opriate extension				
fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Offic timely filed, may reduce any earned patent term adjustment. See 37 C	the shortened statutory period for reply ce later than three months after the mai	originally set in the final	Office action; or				
1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFF							
2. The proposed amendment(s) will not be entered be	ecause:						
(a) 💢 they raise new issues that would require further consideration and/or search (see NOTE below);							
(b) ⊠ they raise the issue of new matter (see Note below);							
(c) they are not deemed to place the application in issues for appeal; and/or	n better form for appeal by mate	rially reducing or sin	nplifying the				
(d) they present additional claims without canceli	ng a corresponding number of f	inally rejected claims	S .				
NOTE: See Continuation Sheet.							
3. Applicant's reply has overcome the following reject	tion(s):						
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a se	eparate, timely filed	amendment				
5. ☑ The a) ☐ affidavit, b) ☐ exhibit, or c) ☑ request for application in condition for allowance because: See		dered but does NO	T place the				
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY t	o issues which were	e newly				
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we			and an				
The status of the claim(s) is (or will be) as follows:							
Claim(s) allowed:							
Claim(s) objected to:							
Claim(s) rejected: 1-3,5-14,23-31 and 37-45.							
Claim(s) withdrawn from consideration:							
8.⊠ The proposed drawing correction filed on 10/16/03	is a)⊠ approved or b)☐ disa	pproved by the Exa	miner.				
9. Note the attached Information Disclosure Statemen	nt(s)(PTO-1449) Paper No(s)	·					
10. Other:							

Continuation Sheet (PTOL-303)

Application No. 009/940,101

Continuation of 2. NOTE: "A method for at least partially inhibiting proliferation or migration of smooth muscle cells in vitro", claimed in 1 represent a departure from the specification and the claims as originally filed. The passages pointed by the applicant do not provide a clear support for "A method for at least partially inhibiting proliferation or migration of smooth muscle cells in vitro". Moreover, said passages clearly stated that the control is total inhibition of proliferation.

The specification and the claims as originally field only support a method for controlling excessive proliferation or migration of smooth muscle cell in vivo..

Continuation of 5. does NOT place the application in condition for allowance because: applicant argument have been fully considered, but have not been found convincing. Applicant arguments addresed amended claims which are not currently entered.

CHRISTINA CHAN
SUPERVISORY PATENT EXAMINER

TECHNOLOGY CENTER 1600